- Researchers have conducted over 200 safe inoculations of volunteers with pneumococcus to study experimental human carriage.
- Studies have found strain differences in carriage rates and that prior carriage protects against future acquisition. The first vaccine study is ongoing.
- Future directions include using the model to test vaccines in high-risk populations, discover vaccines by antigen knockout, and study the role of host immunity and adjuvants. It may also provide insights into microbial ecology following vaccine eradication.
- Key questions include whether the model can be used in elderly or HIV-infected individuals and whether genetically modified pneumococcus can be used.